The results of the ATTAIN-2 study, which involved people with obesity or overweight and type 2 diabetes, showed that the oral ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 ...

The 18th PFS & Injectable Drug Devices Europe Conference returns to London next January, setting the tone for 2026 with a ...

That’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November. Learn from the industry’s ...

Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday ...

It turns out that AbbVie is only interested in buying Gilgamesh's lead drug programme, a psychedelic candidate for major ...

Nucleus RadioPharma, the radiopharmaceutical-focused contract developing and manufacturing organisation founded by Eclipse ...

A new study published in the Nature journal of Mental Health Research shows powerful real-world evidence for the efficacy of ...

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The small-molecule PIKfyve inhibitor ...

Nicox is on track to file for approval of its NCX 470 therapy for eyesight-robbing disease glaucoma after it showed efficacy in a second pivotal trial. The positive data from the Phase 3 Denali ...